A $1.5 million investment in its facilities located near Los Angeles International Airport strengthens DHL’s cold chain capacity, supporting pharmaceutical and healthcare shipments while advancing the company’s long-term health logistics strategy for the Americas.
Bill Roth, general manager and managing partner of IntegriChain’s consulting business, previews his new six-part series by outlining how rising payer fragmentation, divergent cash and insurance models, and supply-chain constraints are reshaping brand strategy.
In today’s Pharma Pulse, the Senate advances legislation to block "biotechnology companies of concern," clinical research ties COVID-19 to REM-dominant sleep apnea, and a new analysis reveals an affordability breaking point for employer-sponsored health insurance.
The CDMO’s latest GMP-qualified line strengthens sterile manufacturing scalability.
In a discussion on global trade disruption, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, explains why pharmaceutical manufacturers must move beyond broad assumptions about tariffs and instead assess trade risk at the individual product level.
In today’s Pharma Pulse, House Republicans block a critical insurance subsidy extension, as new research highlights the oncology benefits of GLP-1s.
The acquisition strengthens CEVA’s global project logistics footprint, adding heavy-lift expertise, specialized engineering talent, and integrated solutions across key regions.
In a discussion on emerging channel strategies, Bill Roth, general manager and managing partner of IntegriChain’s consulting business, explains why DTP models must extend beyond simple cash-pay offerings—highlighting how packaging innovation, insurance-flow backups, and improved patient compliance could unlock new revenue, streamline access, and better reflect clinical outcomes.
In today’s Pharma Pulse, Novartis and Moderna anchor a domestic manufacturing surge, while AI-driven biomarker discovery and physician well-being reshape the future of clinical care.
Traditional market access practices are being transformed by an increasingly rocky landscape of rebate, discount, and direct-distribution practices, but artificial intelligence may clear the pathways to profitability.
The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.
As safety data grows in scale and complexity, AI-powered pharmacovigilance is emerging as a strategic imperative—helping drugmakers improve detection, reduce risk, and strengthen commercial performance.
CoverMyMeds’ Megan Wetzel unpacks the forces behind rising specialty spend, the real impact of access barriers, and how field reimbursement teams help providers guide patients through today’s fragmented system.
Cheryl Allen, BS Pharm, MBA, founding partner, highlights the coming year's focus on navigating an evolving regulatory landscape, while leveraging technology to track the pharmaceutical pipeline, assess analogs, and modernize distribution strategies.
In today’s Pharma Pulse, SOBI strengthens its gout franchise by acquiring Arthrosi Therapeutics for up to $1.5 billion, securing the Phase III asset pozdeutinurad, and much more.
AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.
How pharma can productively coexist with PBMs—and still lower drug costs faster.
A session explores how manufacturers can refine GTN strategy, strengthen pricing governance, and navigate increasingly complex distribution-channel economics, while maintaining both commercial performance and patient affordability.
In a wide-ranging keynote on disruption across pharmaceutical channels, Bill Roth, general manager and managing partner of IntegriChain’s consulting business, outlines why 2025 marks the beginning of a profound regulatory and commercial transformation—from sweeping policy shifts and accelerating WAC reductions to new debates on direct-to-patient strategies and looming instability in medical benefit reimbursement.
In today’s Pharma Pulse, the FDA approves Amgen’s Uplizna (inebilizumab-cdon), the first CD19-targeted therapy for gMG with convenient twice-yearly dosing, and much more.
The fracturing of the US drug market’s traditional model is forcing a demand for a strategic bifurcation to maintain profitability, compliance, and patient access in the decade ahead.
It’s not marketing—it's the activation layer for every dollar spent on patient access and support.
BioCare's Ryan Cort outlines the pharmaceutical industry's "unprecedented sea change," driven by over $400 billion in anticipated revenue loss from generics and biosimilars losing exclusivity.
Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, hopes to use the conference to explore how manufacturers can build the talent and support structures required to keep the US drug supply safe and accessible.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
Counterfeit pharma networks are becoming more sophisticated—leveraging advanced packaging, fragmented logistics, and global trade gaps—making detection harder and patient risk greater than ever.
Rising prescription costs and premiums are forcing more than half of patients to take drastic measures to cover OOP costs.
Various agreements with the Trump administration could have long-term ramifications for Medicaid access and global pricing strategy.
As the FDA ends its phased exemption period for most trading partners, Two Labs’ Michael Rowe warns that DSCSA compliance is entering a far more complex era—one shaped by real-time traceability, digital record requirements, and a transition to a 12-digit NDC.
Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses how the convergence of patient access services with traditional distribution models is setting the stage for medically integrated dispensing to expand beyond oncology.
